Ryan Potter
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Ryan Potter has a total of 30 co-authors. Here are the top co-authors by number of shared publications:
Caitlin Chisholm
Department of Genetics, CHEO, Ottawa, Ontario, Canada
3 shared publicationsElizabeth Sinclair-Bourque
Department of Genetics, CHEO, Ottawa, Ontario, Canada
3 shared publications- Jean McGowan-Jordan
Department of Genetics, CHEO, Ottawa, Ontario, Canada; Department of Pathology and Laboratory Medicine, University of Ottawa, Ottawa, Ontario, Canada
3 shared publications Amanda Smith
Department of Genetics, CHEO, Ottawa, Ontario, Canada; Department of Pathology and Laboratory Medicine, University of Ottawa, Ottawa, Ontario, Canada
2 shared publicationsAudrey Schaffer
Department of Genetics, CHEO, Ottawa, Ontario, Canada
2 shared publications- Landry Nfonsam
Molecular Genetics Laboratory, Hamilton Regional Laboratory Medicine Program, Hamilton Health Sciences Hamilton Ontario Canada
2 shared publications
Latest Publications
- 1 July 2019
- Published by Elsevier in The Journal of Molecular Diagnostics
- Vol. 21 (4) , 602-611
Adopting High-Resolution Allele Frequencies Substantially Expedites Variant Interpretation in Genetic Diagnostic Laboratories
- 1 July 2019
- Published by Elsevier in The Journal of Molecular Diagnostics
- Vol. 21 (4) , 602-611
Adopting High-Resolution Allele Frequencies Substantially Expedites Variant Interpretation in Genetic Diagnostic Laboratories
- 1 May 2019
- Published by Elsevier in The Journal of Molecular Diagnostics
- Vol. 21 (3) , 437-448
Genetic Diagnostic Testing for Inherited Cardiomyopathies
- 1 May 2019
- Published by Elsevier in The Journal of Molecular Diagnostics
- Vol. 21 (3) , 437-448
Genetic Diagnostic Testing for Inherited Cardiomyopathies
- 21 September 2018
- Published by BMJ in Journal of Medical Genetics
- Vol. 56 (6) , 408-412
Leveraging the power of new molecular technologies in the clinical setting requires unprecedented awareness of limitations and drawbacks: experience of one diagnostic laboratory
Background: Advances in molecular technologies and in-silico variant prediction tools offer wide-ranging opportunities in diagnostic settings, yet they also present with significant limitations. Objective: Here, we contextualise the limitations of next-generation sequencing (NGS), multiplex ligation-dependent probe amplification (MLPA) and in-silico prediction tools routinely used by diagnostic laboratories by reviewing specific experiences from our diagnostic laboratory. Methods: We investigated discordant annotations and/or incorrect variant ‘callings’ in exons of 56 genes constituting our cardiomyopathy and connective tissue disorder NGS panels. Discordant variants and segmental duplications (SD) were queried using the National Center for Biotechnology Information (NCBI) Basic Local Alignment Search Tool and the University of California Santa Cruz genome browser, respectively, to identify regions of high homology. Discrepant variant analyses by in-silico models were re-evaluated using updated file entries. Results: We observed a 5% error rate in MYH7 variant ‘calling’ using MLPA, which resulted from >90% homology of the MYH7 probe-binding site to MYH6. SDs were detected in TTN, PKP2 and MYLK. SDs in MYLK presented the highest risk (15.7%) of incorrect variant ‘calling’. The inaccurate ‘callings’ and discrepant in-silico predictions were resolved following detailed investigation into the source of error. Conclusion: Recognising the limitations described here may help avoid incorrect diagnoses and leverage the power of new molecular technologies in diagnostic settings.
- 21 September 2018
- Published by BMJ in Journal of Medical Genetics
- Vol. 56 (6) , 408-412
Leveraging the power of new molecular technologies in the clinical setting requires unprecedented awareness of limitations and drawbacks: experience of one diagnostic laboratory
Background: Advances in molecular technologies and in-silico variant prediction tools offer wide-ranging opportunities in diagnostic settings, yet they also present with significant limitations. Objective: Here, we contextualise the limitations of next-generation sequencing (NGS), multiplex ligation-dependent probe amplification (MLPA) and in-silico prediction tools routinely used by diagnostic laboratories by reviewing specific experiences from our diagnostic laboratory. Methods: We investigated discordant annotations and/or incorrect variant ‘callings’ in exons of 56 genes constituting our cardiomyopathy and connective tissue disorder NGS panels. Discordant variants and segmental duplications (SD) were queried using the National Center for Biotechnology Information (NCBI) Basic Local Alignment Search Tool and the University of California Santa Cruz genome browser, respectively, to identify regions of high homology. Discrepant variant analyses by in-silico models were re-evaluated using updated file entries. Results: We observed a 5% error rate in MYH7 variant ‘calling’ using MLPA, which resulted from >90% homology of the MYH7 probe-binding site to MYH6. SDs were detected in TTN, PKP2 and MYLK. SDs in MYLK presented the highest risk (15.7%) of incorrect variant ‘calling’. The inaccurate ‘callings’ and discrepant in-silico predictions were resolved following detailed investigation into the source of error. Conclusion: Recognising the limitations described here may help avoid incorrect diagnoses and leverage the power of new molecular technologies in diagnostic settings.